Literature DB >> 15618657

Drug transporters: their role and importance in the selection and development of new drugs.

Naomi Mizuno1, Yuichi Sugiyama.   

Abstract

Drug transporters expressed in various tissues play a significant role in drug disposition. By regulating the function of such transporters, it may be possible to eventually develop drugs with ideal pharmacokinetic profiles. In this article, we summarize the significant role played by drug transporters in drug disposition, focusing particularly on their potential use during the drug development process. The ability to manipulate transporter function offers the opportunity of being able to deliver a drug to the target organ, avoiding distribution to other organs (thereby reducing the chance of toxic side-effects), controlling the elimination process, and/or improving oral bioavailability. During drug development, it would be very useful to be able to select a lead compound that may or may not interact with transporters, depending on whether such an interaction is desirable. The use of specific inhibitors of transporters is also an attractive approach to controlling drug disposition, leading to improved efficacy. Currently, optimizing the pharmacokinetic properties of a drug during the early stages of its development is widely accepted as being of great importance. High-throughput screening systems using transporter gene transfected cells or computational (in silico) approaches are efficient tools for assessing transport activity during the early stage of drug development. In addition, drug-drug interactions involving drug transporters and functional genetic polymorphisms of drug transporters are also described. It would also be extremely valuable to be able to quantitatively predict inter-individual pharmacokinetic differences caused by transporter polymorphisms or pharmacokinetic changes caused by drug-drug interactions involving transporters during drug development.

Year:  2002        PMID: 15618657     DOI: 10.2133/dmpk.17.93

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  10 in total

1.  Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry.

Authors:  Anand K Deo; Bhagwat Prasad; Larissa Balogh; Yurong Lai; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2012-02-08       Impact factor: 3.922

Review 2.  Prediction of hepatic clearance in human from in vitro data for successful drug development.

Authors:  Masato Chiba; Yasuyuki Ishii; Yuichi Sugiyama
Journal:  AAPS J       Date:  2009-04-30       Impact factor: 4.009

Review 3.  Modeling kinetics of subcellular disposition of chemicals.

Authors:  Stefan Balaz
Journal:  Chem Rev       Date:  2009-05       Impact factor: 60.622

Review 4.  The role of transporters in the pharmacokinetics of orally administered drugs.

Authors:  Sarah Shugarts; Leslie Z Benet
Journal:  Pharm Res       Date:  2009-06-30       Impact factor: 4.200

Review 5.  Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters.

Authors:  Enoch Cobbina; Fatemeh Akhlaghi
Journal:  Drug Metab Rev       Date:  2017-03-17       Impact factor: 4.518

6.  SLCO1B1 and ABCG2 Gene Polymorphisms in a Thai Population.

Authors:  Punyabhorn Rattanacheeworn; Monpat Chamnanphon; Siriwan Thongthip; Wonngarm Kittanamongkolchai; Natavudh Townamchai; Yingyos Avihingsanon; Udomsak Udomnilobol; Thomayant Prueksaritanont; Suree Jianmongkol; Pajaree Chariyavilaskul
Journal:  Pharmgenomics Pers Med       Date:  2020-10-22

Review 7.  The path for metal complexes to a DNA target.

Authors:  Alexis C Komor; Jacqueline K Barton
Journal:  Chem Commun (Camb)       Date:  2013-05-07       Impact factor: 6.222

Review 8.  The effect of ABCB1 polymorphisms on the outcome of breast cancer treatment.

Authors:  Sonam Tulsyan; Rama Devi Mittal; Balraj Mittal
Journal:  Pharmgenomics Pers Med       Date:  2016-04-27

9.  Chiral Thioxanthones as Modulators of P-glycoprotein: Synthesis and Enantioselectivity Studies.

Authors:  Ana Lopes; Eva Martins; Renata Silva; Madalena M M Pinto; Fernando Remião; Emília Sousa; Carla Fernandes
Journal:  Molecules       Date:  2018-03-10       Impact factor: 4.411

Review 10.  Tumor targeting using liposomal antineoplastic drugs.

Authors:  Jörg Huwyler; Jürgen Drewe; Stephan Krähenbuhl
Journal:  Int J Nanomedicine       Date:  2008
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.